About Molbio Diagnostics Limited IPO
Incorporated in October 2000, Molbio Diagnostics Limited is a healthcare technology company focused on developing and manufacturing point-of-care molecular diagnostic solutions. The company is best known for its proprietary Truenat platform, a portable, battery-operated PCR-based testing system that delivers accurate diagnostic results in less than an hour, making it well suited for hospitals, laboratories, and resource-constrained settings.
Molbio offers diagnostic solutions for more than 30 diseases through 43 molecular test assays, covering tuberculosis (TB), COVID-19, HIV, Hepatitis B & C, HPV, and several other infectious and non-communicable diseases. Beyond molecular diagnostics, the company has expanded into radiology, digital pathology, and breast health screening through strategic acquisitions and partnerships. Its strong in-house research and development capabilities continue to support the launch of new diagnostic products.
The company operates six manufacturing facilities in India and serves customers in over 90 countries, including government healthcare programs, hospitals, diagnostic laboratories, and international health organizations. As of March 31, 2026, Molbio Diagnostics had a workforce of 1,225 employees across research & development, manufacturing, quality assurance, sales, finance, and corporate functions.
Incorporated in October 2000, Molbio Diagnostics Limited is a healthcare technology company focused on developing and manufacturing point-of-care molecular diagnostic solutions. The company is best known for its proprietary Truenat platform, a portable, battery-operated PCR-based testing system that delivers accurate diagnostic results in less than an hour, making it well suite
Molbio Diagnostics IPO Subscription Breakdown
| Investory Category | Subscription Percentage | Amount Raised (₹ Crores) |
|---|---|---|
| Qualified Institutional Buyers (QIBs) | 50% | 40,79,264.5 crores |
| Non-Institutional Investors (NIIs) | 15% | 12,23,779.35 crores |
| Retail Individual Investors (RIIs) | 35% | 28,55,485.15 crores |
Molbio Diagnostics IPO Strengths & Weaknesses
Proprietary Truenat platform with WHO-endorsed molecular diagnostic technology for tuberculosis.
Strong research and development capabilities supported by an extensive patent portfolio.
Scalable business model generating recurring revenue through diagnostic test kits.
Global presence across more than 90 countries with a strong institutional and government customer base.
Diversified healthcare portfolio strengthened through strategic acquisitions and an experienced management team.
Molbio Diagnostics IPO Important Dates & Issue Details
| Allotment Date | Listing Date | Refund Date |
|---|---|---|
| 13 Aug '26 | 17 Aug '26 | 14 Aug '26 |
| Issue Composition: | |
|---|---|
| Face Value | ₹1 per share |
| Total Issue Size | 81,58,529 shares (aggregating up to ₹14,526 crores) |
| Fresh Issue | 24,80,246 shares (aggregating up to ₹24,80,246 crores) |
| Offer for Sale | 91,66,000 shares of ₹1 (aggregating up to ₹91,66,000 crores) |
| Issue Type | Book Building IPO |
| Post-Issue Shareholding Pattern: | |
|---|---|
| Pre-Issue Shareholding | 100 shares |
| Post-Issue Shareholding | 100 shares |
Molbio Diagnostics IPO Lot Size and Investment Details
| Minimum Lot Size | -- |
| Maximum Lot Size (Retail) | -- |
The lot size of Molbio Diagnostics ipo has been designed to ensure broad participation while maintaining optimal price discovery.
How to Apply for Molbio Diagnostics IPO
- Log in to your Choice account
- Select IPO
- Enter the number of lots and your price
- Verify UPI ID
- Complete the transaction on your UPI app
Molbio Diagnostics IPO Contact & Registrar Details
Contact Details
Address
Plot No L-46 Phase I I- D Verna Industrial Area South Goa
Phone Number
Registrar Details
Registrar Name
Kfin Technologies Ltd.
Phone Number
Molbio Diagnostics Lead Manager(s)
| Book Running Lead Manager(s) |
|---|
| Kotak Mahindra Capital Co.Ltd. | IIFL Capital Services Ltd. | Jefferies India Pvt.Ltd. | Motilal Oswal Investment Advisors Ltd. |